Application of a Bayesian method to monitor and adjust vancomycin dosage regimens

A Bayesian method for monitoring vancomycin concentrations and adjusting regimens in patients with unstable renal function by using a two-compartment population model was evaluated with a personal computer. The population model was derived from data from 12 cardiac outpatients who received single doses of vancomycin. The performance of the method was then tested in 27 acutely ill patients who received multiple doses of vancomycin. Significant renal impairment was observed in 15 patients. Renal function changed in 15 patients. The vancomycin concentrations in the patients with changing renal function were not at steady state during the observation times. Two concentrations in serum (peak and then trough, or trough and then peak) were fitted along with the population model to individualize the parameter values for each patient. All the subsequent concentrations in serum for each patient were then predicted by using the parameter values for each patient. Future concentrations of 118 serum samples were predicted. The mean absolute prediction error was 3.6 +/- 4.5 micrograms/ml, and the mean prediction error was -0.7 +/- 5.3 micrograms/ml. These results confirm that a two-compartment pharmacokinetic model can be sufficiently individualized with the knowledge of just two concentrations of drug in patient serum; it is possible to predict closely subsequent concentrations in serum, and dosing regimens for individual patients can be well adjusted to achieve the chosen therapeutic goals.

[1]  J. Rotschafer,et al.  Evaluation of a Two‐Compartment Bayesian Forecasting Program for Predicting Vancomycin Concentrations , 1989, Therapeutic drug monitoring.

[2]  A Schumitzky,et al.  A program package for simulation and parameter estimation in pharmacokinetic systems. , 1979, Computer programs in biomedicine.

[3]  R. Smith,et al.  Bacteremia in patients undergoing oral procedures. Study following parenteral antimicrobial prophylaxis as recommended by the American Heart Association, 1977. , 1988, Archives of internal medicine.

[4]  J. Rotschafer,et al.  Individualizing vancomycin dosage regimens: one- versus two-compartment Bayesian models. , 1989, Therapeutic drug monitoring.

[5]  R. Jelliffe Clinical Applications of Pharmacokinetics and Control Theory: Planning, Monitoring, and Adjusting Dosage Regimens of Aminoglycosides, Lidocaine, Digitoxin, and Digoxin , 1986 .

[6]  J. Garrelts,et al.  Accuracy of Bayesian, Sawchuk-Zaske, and nomogram dosing methods for vancomycin. , 1987, Clinical pharmacy.

[7]  W. Farrar,et al.  ‘VANCOMYCIN REVISITED’ , 1978, Annals of internal medicine.

[8]  D. T. Rock,et al.  Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers , 1987, Antimicrobial Agents and Chemotherapy.

[9]  H. Lode,et al.  Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers , 1988, Antimicrobial Agents and Chemotherapy.

[10]  J. Rotschafer,et al.  Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations , 1982, Antimicrobial Agents and Chemotherapy.

[11]  M E Burton,et al.  Evaluation of a Bayesian Method for Predicting Vancomycin Dosing , 1989, DICP : the annals of pharmacotherapy.

[12]  D. Krogstad,et al.  Single‐Dose Kinetics of Intravenous Vancomycin , 1980, Journal of clinical pharmacology.

[13]  C H Nightingale,et al.  Pharmacokinetics of vancomycin in anuria. , 1981, Reviews of infectious diseases.

[14]  W. Bennett,et al.  Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects , 1988, Clinical pharmacology and therapeutics.

[15]  J. Kovarik,et al.  Evaluation of the vancomycin-clearance:creatinine-clearance relationship for predicting vancomycin dosage. , 1985, Clinical pharmacy.

[16]  A Forrest,et al.  An evaluation of optimal sampling strategy and adaptive study design , 1988, Clinical pharmacology and therapeutics.

[17]  W. Wilson,et al.  Vancomycin therapy for infective endocarditis. , 1981, Reviews of infectious diseases.

[18]  R. Jelliffe,et al.  A computer program for estimation of creatinine clearance from unstable serum creatinine levels, age, sex, and weight , 1972 .

[19]  L B Sheiner,et al.  Forecasting individual pharmacokinetics , 1979, Clinical pharmacology and therapeutics.

[20]  D J Greenblatt,et al.  Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. , 1981, Annals of internal medicine.

[21]  K. Lake,et al.  Evaluation of a Method for Initiating Vancomycin Therapy: Experience in 205 Patients , 1988, Pharmacotherapy.

[22]  J. Rotschafer,et al.  Vancomycin pharmacokinetics in patients with various degrees of renal function , 1988, Antimicrobial Agents and Chemotherapy.

[23]  W. Keane,et al.  Pharmacokinetics of vancomycin in patients with various degrees of renal function , 1984, Antimicrobial Agents and Chemotherapy.

[24]  A Forrest,et al.  A prospective evaluation of optimal sampling theory in the determination of the steady‐state pharmacokinetics of piperacillin in febrile neutropenic cancer patients , 1989, Clinical pharmacology and therapeutics.